BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/24/2015 11:11:00 AM | Browse: 1448 | Download: 3254
 |
Received |
|
2015-06-03 10:15 |
|
Peer-Review Started |
|
2015-06-03 16:38 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2015-08-27 16:52 |
|
Revised |
|
2015-09-03 11:43 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2015-10-12 16:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2015-10-20 09:18 |
|
Articles in Press |
|
2015-10-20 09:18 |
|
Edit the Manuscript by Language Editor |
|
2015-11-23 14:41 |
|
Typeset the Manuscript |
|
2015-12-10 09:13 |
|
Publish the Manuscript Online |
|
2015-12-24 11:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yoshimasa Saito, Hiroshi Serizawa, Yukako Kato, Masaru Nakano, Masahiko Nakamura, Hidetsugu Saito, Hidekazu Suzuki and Takanori Kanai |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Research Grant of Kitasato Institute Hospital |
|
|
| Corresponding Author |
Yoshimasa Saito, MD, PhD, Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512,
Japan. saito-ys@pha.keio.ac.jp
|
| Key Words |
CYP2C19; Esomeprazole; Helicobacter pylori; Pepsinogen; Proton pump inhibitor |
| Core Tip |
Esomeprazole (EPZ) is considered to be more effective for inhibition of gastric acid secretion than other first-generation proton pump inhibitors (PPIs) because its metabolism is not influenced by CYP2C19 genotype. In the present study, however, first-line eradication by EPZ-based triple therapy for patients with Helicobacter pylori (H. pylori)-positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with triple therapies with other first-generation PPIs in the Japanese population. Unlike previous studies, our results suggest that there is no advantage for EPZ-based triple therapy on H. pylori eradication in comparison with other first-generation PPIs.
|
| Publish Date |
2015-12-24 11:11 |
| Citation |
Saito Y, Serizawa H, Kato Y, Nakano M, Nakamura M, Saito H, Suzuki H, Kanai T. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. World J Gastroenterol 2015; 21(48): 13548-13554 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i48/13548.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i48.13548 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
